MNPR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MN

Mkt Cap

$465.4M

Volume

129.07K

Next Earnings

November 12th

Loading chart

MN

MNPRMonopar Therapeutics Inc. Common Stock

MNPR

Pay with—

Available Balance0.00

MN

Mkt Cap

$481.9M

Volume

129.07K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026Monopar Therapeutics announced Phase 2 trial results for ALXN1840 (tiomolibdate choline) in treatment-experienced Wilson disease patients. The study demonstrated stabilization or improvement in liver pathology across multiple histologic measures, significant neurologic improvements in UWDRS scores, and improved quality of life. The drug was generally well tolerated with mostly Grade 1-2 adverse events.GlobeNewswire Inc. · Jun 1, 2026

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMonopar Therapeutics announced Q1 2026 financial results with cash reserves of $137.5 million and a net loss of $3.9 million. The company presented Phase 3 FoCus trial data showing ALXN1840 (tiomolibdate choline) demonstrated greater neurologic benefit versus standard-of-care in Wilson disease patients. The NDA submission to the FDA remains on track for mid-2026, with new Chief Commercial and Strategy Officer Susan Rodriguez leading commercial readiness activities.GlobeNewswire Inc. · May 14, 2026

Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business UpdateMonopar Therapeutics announced 2025 financial results with a net loss of $13.7 million and cash reserves of $140.4 million expected to support operations through at least December 2027. The company plans to submit a New Drug Application for ALXN1840 in mid-2026 for Wilson disease treatment, supported by positive clinical data presentations and FDA interactions. The company also strengthened its leadership team and balance sheet through a $91.9 million public offering.GlobeNewswire Inc. · Mar 27, 2026

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025Monopar Therapeutics presented new data at AASLD showing that ALXN1840 (tiomolybdate choline) rapidly improved copper balance in Wilson disease patients through increased fecal copper excretion.GlobeNewswire Inc. · Nov 9, 2025

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsMonopar Therapeutics is conducting a $135 million underwritten offering of common stock and pre-funded warrants, with plans to use proceeds for general corporate purposes and a stock repurchase from Tactic Pharma.GlobeNewswire Inc. · Sep 24, 2025

Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease PatientsMonopar Therapeutics published a Letter to the Editor in the Journal of Hepatology, reanalyzing their Phase 2 ALXN1840-WD-204 study for Wilson disease. The new analysis shows that ALXN1840 statistically significantly improved copper balance by accounting for additional routes of copper loss.GlobeNewswire Inc. · Sep 24, 2025

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent DevelopmentsMonopar Therapeutics has in-licensed ALXN-1840, a late-stage drug candidate for Wilson disease, from Alexion, AstraZeneca Rare Disease. The company also has two novel radiopharma clinical trials active and enrolling patients with advanced solid cancers.GlobeNewswire Inc. · Nov 8, 2024

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common StockMonopar Therapeutics, a clinical-stage biotechnology company, announced the pricing of a $19.2 million public offering of its common stock at $16.25 per share. The proceeds will be used for general corporate purposes, including research and development, clinical trials, and working capital.GlobeNewswire Inc. · Oct 29, 2024

Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled “Evaluation of Anti-uPAR Antibody as a Radiopharmaceutical for Imaging and Treatment of Solid Tumors” has been accepted as a “Top-Rated Oral Presentation” within the Scientific Program of the European Association of Nuclear Medicine (EANM) 2024 Annual Congress to be held on October 19-23, 2024 in Hamburg, Germany.GlobeNewswire Inc. · Jun 25, 2024

Monopar and NorthStar Amend & Extend CollaborationHighlights:GlobeNewswire Inc. · Jun 11, 2024

to start trading

MN

MNPRMonopar Therapeutics Inc. Common Stock

MNPR

Pay with—

Available Balance0.00

Your PositionYou don't own any MNPR yet.

Related Tickers

Earnings